The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure
Hypertension, Congestive Heart Failure
About this trial
This is an interventional treatment trial for Hypertension focused on measuring HYPERTENSION, HEART FAILURE, PEPTIDE, valsartan
Eligibility Criteria
Inclusion Criteria: Male or female 25-85 years of age, inclusive Past diagnosis of hypertension for a min 1 year Patients with an established treatment regimen for hypertension with one or more agents for a minimum period of 2 months BP is considered adequately controlled with DBP < 90mmHg Elevated BNP levels both in bedside test (62pg/ml) and after validation of a separate blood sample (40pg/ml) in the central laboratory LV ejection fraction ³ 45% LVH defined as myocardial mass ³ 116 g /m2 in males and 104 g/m2 in females At least one of the following parameters of diastolic dysfunction E/A < 1 for the patients who are younger than 55 years or < 0.8 for the patients whose age is ³ 55 years (full year), or DT > 220 ms, or IVRT > 90 ms Exclusion Criteria: • Present use of ACE inhibitor Other protocol-defined exclusion criteria may apply. -